Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Tzu‐Min Yeh et al.|The Lancet|2021Cited by 1.7k
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)Deepu Madduri, Jesús G. Berdeja, Saad Z. Usmani et al.|Blood|2019Cited by 120
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple MyelomaDeepu Madduri, Thomas Martin, Jesús G. Berdeja et al.|Blood|2020Cited by 94
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.Jesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|Journal of Clinical Oncology|2020Cited by 78
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell SubsetEnrique Zudaire, Sundar Jagannath, Deepu Madduri et al.|Blood|2019Cited by 29